Biosimilar of biphasic human insulin: results of a double-blind, randomized, comparative, cross-sectional clinical study of pharmacokinetics

Justification. The prevalence of type 2 diabetes is extremely high, and the number of such patients is constantly increasing. In 30-40% of patients, only insulin therapy can achieve compensation for the disease. Therapy with ready-made mixtures is considered as an alternative option in the initiation and intensification of insulin therapy. Rinsulin® mix 30/70 is a domestic biosimilar (bioanalogue) of Humulin® M3, a combination of a 30% solution of human insulin and a 70% suspension of insulin-isofan. The clinical research program for biosimilars of insulin preparations includes pharmacology studies: pharmacokinetics, pharmacodynamics and clinical safety research. Purpose. Evaluation of the biosimilarity of Rinsulin® mix 30/70 (bioanalog) and Humulin® M3 (original) preparations in the conditions of hyperinsulinemic euglycemic clamp in healthy volunteers. Materials and methods. The study was conducted on healthy male volunteers aged 18 to 50 years. Study design is a double-blind, randomized, crossover study of the comparative pharmacokinetics of drugs. The drugs were injected subcutaneously into the anterior abdominal wall at a dose of 0.4 IU / kg once. The duration of blood sampling to determine the pharmacokinetic parameters was 24 hours: the concentration of insulin in the blood was determined by enzyme-linked immunosorbent assay. Based on the level of glycemia, the glucose infusion rate was adjusted, the data of which were used to calculate the pharmacodynamic parameters. Results and discussion. Comparability of the main pharmacokinetic and pharmacodynamic characteristics of the Rinsulin® mix 30/70 and Humulin® M3 preparations in the conditions of hyperinsulinemic euglycemic clamp in healthy volunteers was noted. The confidence interval for the logarithmically transformed ratio of the values of the parameter C_ins.max was 87.31-105.26%, and AuC_ins.0-12 - 85.23-110.90%, which falls within the limits set by regulatory documents 80-125% to establish comparability between drugs. This confirms the high similarity of the reproduced Rinsulin® Mix 30/70 to the original drug. Of particular clinical significance is the synchronous onset of drug action, the time of onset of the maximum effect and duration of action. Adverse events in the study associated with the introduction of drugs were not recorded. Conclusions. Rinsulin® mix 30/70 and Humulin® M3 are equivalent.

инсулин генно-инженерный человеческий двухфазный, биосимиляр, фармакокинетика, фармакодинамика, гиперинсулинемический эугликемический клэмп, insulin genetically engineered human biphasic, biosimilar, pharmacokinetics, pharmacodynamics, hyperinsulinemic euglycemic clamp

1. Федеральный регистр больных сахарным диабетом. [Federal'nyj registr bol'nyh saharnym diabetom [Internet] (In Russ).] URL: http://diaregistry.ru. (lата обращения 03.2019).

2. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 годы» / Под редакцией И.И. Дедова, М.В. Шестаковой // Сахарный диабет. 2013. Спецвыпуск. [Rezul'taty realizacii podprogrammy «Saharnyj diabet» Federal'noj celevoj programmy «Preduprezhdenie i bor'ba s social'no znachimymi zabolevaniyami 2007–2012 gody» / Ed by I.I. Dedova, M.V. SHestakovoj. Diabetes mellitus. 2013. Specvypusk. (In Russ).]

3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 8-й выпуск. – М.: УП ПРИНТ; 2017. [Standards of Specialized Diabetes Care / Ed. by Dedov II, Shestakova MV, Mayorov AY. 8th Edition. Мoscow: UP PRINT; 2017. (In Russ).] DOI: 10.14341/DM20171S8

4. Джавахишвили Т.Ш., Романцова Т.И., Роик О.В. Динамика массы тела у больных сахарным диабетом 2 типа в течение первого года инсулинотерапии // Ожирение и метаболизм. – 2010. – № 4. – С. 13–19. [Dzhavahishvili TSH, Romancova TI, Roik OV. Dinamika massy tela u bol'nyh saharnym diabetom 2 tipa v techenie pervogo goda insulinoterapii. Ozhirenie i metabolizm. 2010;4:13–19. (In Russ).]

5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009 Jan;32(1):193–203. DOI: 10.2337/dc08-9025

6. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (EMEA/CHMP/BMWP/32775/2005_Rev. 1).

7. Решение № 89 от 3 ноября 2016 года "Об утверждении правил проведения исследований биологических лекарственных средств Евразийского экономического союза», глава 15.7 "Доклиническая и клиническая разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих рекомбинантный инсулин и аналоги инсулина". [Decision № 89 of Nov 3 2016 "Ob utverzhdenii pravil provedeniya issledovaniy biologicheskikh lekarstvennykh sredstv Evraziyskogo ekonomicheskogo soyuza", glava 15.7 "Doklinicheskaya i klinicheskaya razrabotka bioanalogichnyh (biopodobnyh) lekarstvennyh preparatov, soderzhashchih rekombinantnyj insulin i analogi insulina". (In Russ).]

8. Разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих в качестве фармацевтической субстванции генно-инженерный инсулин человека или аналоги инсулина человека // Руководство по экспертизе лекарственных средств. Том IV. – М.: Полиграфплюс; 2014. [Razrabotka bioanalogichnykh (biopodobnykh) lekarstvennykh preparatov, soderzhashchikh v kachestve farmatsevticheskoy substvantsii gennoinzhenernyy insulin cheloveka ili analogi insulina cheloveka. In: Rukovodstvo po ekspertize lekarstvennykh sredstv. Vol. IV. Moscow: Poligraf-plyus; 2014. (In Russ).]

9. Heinemann L, Anderson JH. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004 Oct;6(5):698–718. DOI: 10.1089/dia.2004.6.698

10. Heise T, Zijlstra E, Nosek L, et al. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016 Oct;18(10):962-72. DOI: 10.1111/dom.12703

11. Hompesch M, Rave K. An Analysis of How to Measure Glucose during Glucose Clamps: Are Glucose Meters Ready for Research? J. Diabetes Sci. Technol. 2008; 2(5):896-898. DOI: 10.1177/193229680800200522

12. Guideline on similar biological medicinal products (CHMP/437/04 Rev. 1).

13. Rabiee A, Magruder JT, Grant C, et al. Accuracy and reliability of the Nova StatStrip® glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010 Sep 1;4(5):1195–201. DOI: 10.1177/193229681000400519

14. Lindquist KA, Chow K, West A, et al. The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population. Diabetes technology & therapeutics. 2014;16(5):298–302.

15. Woodworth JR, Howey DC, Bowsher RR, et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care. 1994;17(5):366–371.